Supply Agreement Clinical Trial

1. CYRAMZA® is a registered trademark owned by Eli Lilly and its subsidiaries or related companies, or licensed to Eli Lilly and its subsidiaries.2. F.M Johnston, Mr. Beckman. Updated stomach cancer management. Latest Oncology Reports 2019 (21), 673.M. Orditura, G. Galizia, V. Sforza et al. Treatment of Stomach Cancers, World Journal of Gastroenterology 2014 (20), 1635-16494. A.

Bass, V. Thorsson, I. Shmulevich et al. Complete molecular characterization of gastenocarcinoma. Nature 2014 (513), 202-2095. T. G. Hall, Y. Yu, S.

Eathiraj et al. Preclinical activity of ARQ 087, a new inhibitor for FGFR dysregulation. PLoS ONE 2016, 11 (9), e01625946. R. Porta, R. Borea, A. Coelho et al. FGFR a promising drug target in cancer: molecular biology and new drugs.

Oncology/Hematology Reviews 2017 (113), 256-2677. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape for cancer: analysis of 4,853 tumors by sequencing the next generation. Clinical Cancer Research 2016 (22), 259-2678. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): an FGFR/CSF1R inhibitor that is active in PDX models of urothel cancer.

Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C129. Mr. A. Cannarile, M. Weisser, W. Jacob et al. Factor 1 receptor inhibitors (CSF1R) in cancer treatment. Journal for ImmunoTherapy of Cancer 2017, 5:5310.

Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockage reprograms tumor-infiltrated macrophages and improves response to T-Zell Checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-506911.

E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages prevent CD8-T cells from reaching tumor cells and limit the effectiveness of anti-PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E405012. V. Mazzaferro, B.

F. El-Rayes, M. Droz dit Busset et al. Derazantinib (ARQ 087) in case of FGFR2-positive gene intrahepatischem cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. Signature: NCT0175292013. FIDES-01: qualifiers: NCT0323031814. FIDES-02: qualifiers: NCT0404561315. FIDES-03: Identity: NCT04604132 Immuno-oncology is a top priority for Merck KGaA, Darmstadt, Germany, and Pfizer Inc.